إسرائيل - الإنجليزية - Ministry of Health

inovamed ltd - bicalutamide - film coated tablets - bicalutamide 150 mg - bicalutamide - bicalutamide - in patients with locally advanced prostate cancer (t3 - t4 any n m0 t1 -t2 n+ m0), bicalutamide 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

major pharmaceuticals - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide 50 mg - bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d 2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see clinical studies (14.2)]. bicalutamide is contraindicated in: bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. bicalutamide has no indication for women, and should not be used in this population. bicalutamide can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)]. risk summary bicalutamide is contraindicated for use in pregnant women because it c

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide 50 mg - bicalutamide tablets, usp 50 mg daily are indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d2 metastatic carcinoma of the prostate. bicalutamide tablets, usp 150 mg daily are not approved for use alone or with other treatments [see clinical studies (14.2)]. bicalutamide is contraindicated in: - hypersensitivity bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. - women bicalutamide has no indication for women, and should not be used in this population. - pregnancy bicalutamide can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)]. risk summary bicalutamide is contraindicated for use in pregnant women because it can cause fetal harm. bicalutamide is not indicated for use in females. there are no human data on t

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

bryant ranch prepack - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide 50 mg - bicalutamide tablets 50 mg daily are indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily are not approved for use alone or with other treatments [see clinical studies (14.2) ]. bicalutamide tablets are contraindicated in: - hypersensitivity bicalutamide tablets are contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. - women bicalutamide tablets have no indication for women, and should not be used in this population. - pregnancy bicalutamide tablets can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1) ]. risk summary bicalutamide is contraindicated for use in pregnant women because it can cause fetal harm. bicalutamide is not indicated for use in f

إسرائيل - الإنجليزية - Ministry of Health

teva israel ltd - bicalutamide - tablets - bicalutamide 50 mg - bicalutamide - bicalutamide - for the treatment of advanced prostate cancer in combination with lhrh analog therapy or surgical castration.

إسرائيل - الإنجليزية - Ministry of Health

inovamed ltd - bicalutamide - film coated tablets - bicalutamide 50 mg - bicalutamide - bicalutamide - for the treatment of advanced prostate cancer in combination with luteinising hormone-releasing hormone (lhrh) analog therapy or surgical castration.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - bicalutamide -

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - bicalutamide - film-coated tablet - 50 milligram(s) - anti-androgens; bicalutamide

مالطا - الإنجليزية - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - bicalutamide - film-coated tablet - bicalutamide 50 mg - endocrine therapy

مالطا - الإنجليزية - Medicines Authority

accord healthcare limited - bicalutamide - film-coated tablet - bicalutamide 50 mg - endocrine therapy